Evidence map›Paper›PMID 40050446›Full record

ReviewNPJ precision oncology2025

Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma.

Vinita Akula, Lily Chen, Yusuf Acikgoz, Katherine Klein, Betul Gok Yavuz, Lokman Cevik, Tarik Demir, Ashish Manne, Ilyas Sahin, Ahmed Kaseb and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vinita AkulaDepartment of Internal Medicine, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Lily ChenDepartment of Internal Medicine, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Yusuf AcikgozDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Katherine KleinDepartment of Internal Medicine, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Betul Gok YavuzDepartment of Medicine, University of Missouri, Columbia, MO, USA.
Lokman CevikDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Tarik DemirDivision of Hematology and Oncology Developmental Therapeutics Institute, Northwestern University, Chicago, IL, USA.
Ashish ManneDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ilyas SahinDivision of Hematology & Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA.
Ahmed KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elshad HasanovDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Elshad.hasanov@osumc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

Identifiers

PMID40050446
PMCPMC11885445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.